Study Stopped
The proposed analysis was not feasible.
Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC)
HNCAX01
Body Composition Evaluation as a Prognosis Determinant in Head and Neck Squamous Cell Carcinoma (HNSCC)
1 other identifier
observational
N/A
1 country
1
Brief Summary
This is a retrospective study in patients with cancer of the oral cavity, pharynx, and larynx. Imaging exams of these patients will be analyzed with the objective of developing and validating a clinically applicable method for evaluation of cachexia and/or sarcopenia in a patient with head and neck cancer from musculature imaging of the neck. Indeed, the prognostic influence of body composition will be evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jul 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 27, 2019
CompletedFirst Posted
Study publicly available on registry
July 1, 2019
CompletedStudy Start
First participant enrolled
July 30, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2021
CompletedApril 20, 2022
April 1, 2022
1.6 years
June 27, 2019
April 13, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Overall survival in HNSCC
Survival will be measured to understand the prognostic impact of skeletal muscle index in HNSCC
1 year
Secondary Outcomes (1)
Skeletal muscle index of L3 and C3
1 years
Eligibility Criteria
Patients who have histological or cytological evidence of oropharynx squamous cell carcinoma, oral cavity, larynx or hypopharynx, locally advanced treated only at Sao Paulo Cancer Institute (ICESP).
You may qualify if:
- Patients who have histological or cytological evidence of oropharynx squamous cell carcinoma, oral cavity, larynx or hypopharynx, locally advanced treated only at Sao Paulo Cancer Institute (ICESP).
You may not qualify if:
- patients with no tomography available.
- head and neck cancer with tumor at other sites such as thyroid, paranasal sinus, skin and nasopharynx, or other histology other than squamous cell carcinoma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Instituto do Câncer do Estado de São Paulo
São Paulo, São Paulo, 01246-000, Brazil
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 27, 2019
First Posted
July 1, 2019
Study Start
July 30, 2019
Primary Completion
March 1, 2021
Study Completion
March 1, 2021
Last Updated
April 20, 2022
Record last verified: 2022-04